{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T10:20:29Z","timestamp":1779272429928,"version":"3.51.4"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100032277","name":"RespireRx Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032277","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jpsychires.2025.04.019","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T04:43:58Z","timestamp":1744346638000},"page":"145-153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Antipsychotic-like pharmacological profile of the low impact ampakine CX691 (farampator): Implications for the use of low impact ampakines in the treatment of schizophrenia"],"prefix":"10.1016","volume":"186","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3775-7712","authenticated-orcid":false,"given":"Daniel P.","family":"Radin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9208-6398","authenticated-orcid":false,"given":"Rok","family":"Cerne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9145-8548","authenticated-orcid":false,"given":"Jodi L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey M.","family":"Witkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnold","family":"Lippa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jpsychires.2025.04.019_bib1","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0022-3565(25)20645-0","article-title":"Effects of a memory-enhancing drug on DL-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor currents and synaptic transmission in hippocampus","volume":"278","author":"Arai","year":"1996","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"5","key":"10.1016\/j.jpsychires.2025.04.019_bib2","doi-asserted-by":"crossref","first-page":"583","DOI":"10.2174\/138945007780618490","article-title":"Pharmacology of ampakine modulators: from AMPA receptors to synapses and behavior","volume":"8","author":"Arai","year":"2007","journal-title":"Curr. Drug Targets"},{"issue":"4","key":"10.1016\/j.jpsychires.2025.04.019_bib3","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1124\/mol.58.4.802","article-title":"Effects of the potent ampakine CX614 on hippocampal and recombinant AMPA receptors: interactions with cyclothiazide and GYKI 52466","volume":"58","author":"Arai","year":"2000","journal-title":"Mol. Pharmacol."},{"issue":"3","key":"10.1016\/j.jpsychires.2025.04.019_bib4","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1124\/jpet.102.040360","article-title":"Benzamide-type AMPA receptor modulators form two subfamilies with distinct modes of action","volume":"303","author":"Arai","year":"2002","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"6","key":"10.1016\/j.jpsychires.2025.04.019_bib5","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.neuropharm.2010.05.011","article-title":"Withdrawal from chronic amphetamine produces persistent anxiety-like behavior but temporally-limited reductions in monoamines and neurogenesis in the adult rat dentate gyrus","volume":"59","author":"Barr","year":"2010","journal-title":"Neuropharmacology"},{"issue":"5","key":"10.1016\/j.jpsychires.2025.04.019_bib6","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.neuron.2007.01.030","article-title":"The interaction between Stargazin and PSD-95 regulates AMPA receptor surface trafficking","volume":"53","author":"Bats","year":"2007","journal-title":"Neuron"},{"key":"10.1016\/j.jpsychires.2025.04.019_bib7","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.schres.2020.01.025","article-title":"AMPA receptor subunit localization in schizophrenia anterior cingulate cortex","volume":"249","author":"Benesh","year":"2022","journal-title":"Schizophr. Res."},{"issue":"5","key":"10.1016\/j.jpsychires.2025.04.019_bib8","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1089\/cap.2006.16.525","article-title":"Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial","volume":"16","author":"Berry-Kravis","year":"2006","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"1\u20133","key":"10.1016\/j.jpsychires.2025.04.019_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2012.02.033","article-title":"Targeting glutamate system for novel antipsychotic approaches: relevance for residual psychotic symptoms and treatment resistant schizophrenia","volume":"682","author":"de Bartolomeis","year":"2012","journal-title":"Eur. J. Pharmacol."},{"issue":"11","key":"10.1016\/j.jpsychires.2025.04.019_bib10","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1017\/S0033291717000435","article-title":"Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors","volume":"47","author":"Demjaha","year":"2017","journal-title":"Psychol. Med."},{"issue":"1","key":"10.1016\/j.jpsychires.2025.04.019_bib11","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.schres.2013.03.010","article-title":"Transmembrane AMPA receptor regulatory protein (TARP) dysregulation in anterior cingulate cortex in schizophrenia","volume":"147","author":"Drummond","year":"2013","journal-title":"Schizophr. Res."},{"issue":"20","key":"10.1016\/j.jpsychires.2025.04.019_bib12","doi-asserted-by":"crossref","first-page":"11047","DOI":"10.1073\/pnas.191353298","article-title":"Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter","volume":"98","author":"Gainetdinov","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.jpsychires.2025.04.019_bib13","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0022-3565(24)38148-0","article-title":"Synergistic interactions between ampakines and antipsychotic drugs","volume":"289","author":"Johnson","year":"1999","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"6","key":"10.1016\/j.jpsychires.2025.04.019_bib14","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.22m14458","article-title":"The economic burden of schizophrenia in the United States","volume":"83","author":"Kadakia","year":"2022","journal-title":"J. Clin. Psychiatr."},{"issue":"18","key":"10.1016\/j.jpsychires.2025.04.019_bib15","doi-asserted-by":"crossref","first-page":"4969","DOI":"10.1523\/JNEUROSCI.5561-06.2007","article-title":"New transmembrane AMPA receptor regulatory protein isoform, gamma-7, differentially regulates AMPA receptors","volume":"27","author":"Kato","year":"2007","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.jpsychires.2025.04.019_bib16","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0006-8993(96)01049-9","article-title":"Effects of an AMPA receptor modulator on methamphetamine-induced hyperactivity in rats","volume":"738","author":"Larson","year":"1996","journal-title":"Brain Res."},{"issue":"1","key":"10.1016\/j.jpsychires.2025.04.019_bib17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1523\/JNEUROSCI.20-01-00008.2000","article-title":"Positive modulation of AMPA receptors increases neurotrophin expression by hippocampal and cortical neurons","volume":"20","author":"Lauterborn","year":"2000","journal-title":"J. Neurosci. : Off. J. Soc. Neurosci."},{"issue":"10","key":"10.1016\/j.jpsychires.2025.04.019_bib18","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.tins.2006.07.007","article-title":"Ampakines and the threefold path to cognitive enhancement","volume":"29","author":"Lynch","year":"2006","journal-title":"Trends Neurosci."},{"issue":"1","key":"10.1016\/j.jpsychires.2025.04.019_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.273","article-title":"Glutamatergic and GABAergic gene sets in attention-deficit\/hyperactivity disorder: association to overlapping traits in ADHD and autism","volume":"7","author":"Naaijen","year":"2017","journal-title":"Transl. Psychiatry"},{"issue":"6","key":"10.1016\/j.jpsychires.2025.04.019_bib20","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0028-3908(01)00133-2","article-title":"Mechanism and impact of allosteric AMPA receptor modulation by the ampakine CX546","volume":"41","author":"Nagarajan","year":"2001","journal-title":"Neuropharmacology"},{"issue":"1\u20132","key":"10.1016\/j.jpsychires.2025.04.019_bib21","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0169-328X(96)00280-X","article-title":"Comparison of the effects of an ampakine with those of methamphetamine on aggregate neuronal activity in cortex versus striatum","volume":"46","author":"Palmer","year":"1997","journal-title":"Brain Res. Mol. Brain Res."},{"issue":"4","key":"10.1016\/j.jpsychires.2025.04.019_bib22","first-page":"456","article-title":"The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and A roadmap for future research","volume":"18","author":"Potkin","year":"2020","journal-title":"Focus (Am Psychiatr Publ)"},{"issue":"10","key":"10.1016\/j.jpsychires.2025.04.019_bib23","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1523\/JNEUROSCI.4834-04.2005","article-title":"Stargazin reduces desensitization and slows deactivation of the AMPA-type glutamate receptors","volume":"25","author":"Priel","year":"2005","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.jpsychires.2025.04.019_bib24","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1471-4159.2011.07565.x","article-title":"Clozapine functions through the prefrontal cortex serotonin 1A receptor to heighten neuronal activity via calmodulin kinase II-NMDA receptor interactions","volume":"120","author":"Purkayastha","year":"2012","journal-title":"J. Neurochem."},{"issue":"1","key":"10.1016\/j.jpsychires.2025.04.019_bib25","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3390\/futurepharmacol4010012","article-title":"Low-impact ampakine CX1739 exerts pro-cognitive effects and reverses opiate-induced respiratory depression in rodents","volume":"4","author":"Radin","year":"2024","journal-title":"Futu. Pharmaco."},{"key":"10.1016\/j.jpsychires.2025.04.019_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177317","article-title":"Safety, tolerability and pharmacokinetic profile of the low-impact ampakine CX717 in young healthy male subjects and elderly healthy male and female subjects","author":"Radin","year":"2025","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.jpsychires.2025.04.019_bib27","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/cpdd.1475","article-title":"Safety, tolerability, and pharmacokinetic profile of the low-impact ampakine CX1739 in young healthy volunteers","volume":"14","author":"Radin","year":"2025","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.jpsychires.2025.04.019_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.852940","article-title":"Lucanthone targets lysosomes to perturb glioma proliferation, chemoresistance and stemness, and slows tumor growth in vivo","volume":"12","author":"Radin","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jpsychires.2025.04.019_bib29","first-page":"1","article-title":"Preclinical characterization of a water-soluble low-impact ampakine prodrug, CX1942 and its active moiety, CX1763","author":"Radin","year":"2024","journal-title":"Future Med. Chem."},{"issue":"3","key":"10.1016\/j.jpsychires.2025.04.019_bib30","doi-asserted-by":"crossref","first-page":"494","DOI":"10.3390\/futurepharmacol4030028","article-title":"Preclinical pharmacology of the low-impact ampakine CX717","volume":"4","author":"Radin","year":"2024","journal-title":"Futu. Pharmaco."},{"issue":"11","key":"10.1016\/j.jpsychires.2025.04.019_bib31","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/nn1551","article-title":"TARP gamma-8 controls hippocampal AMPA receptor number, distribution and synaptic plasticity","volume":"8","author":"Rouach","year":"2005","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.jpsychires.2025.04.019_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/srep46288","article-title":"Olanzapine, but not clozapine, increases glutamate release in the prefrontal cortex of freely moving mice by inhibiting D-aspartate oxidase activity","volume":"7","author":"Sacchi","year":"2017","journal-title":"Sci. Rep."},{"issue":"7906","key":"10.1016\/j.jpsychires.2025.04.019_bib33","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41586-022-04556-w","article-title":"Rare coding variants in ten genes confer substantial risk for schizophrenia","volume":"604","author":"Singh","year":"2022","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.jpsychires.2025.04.019_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.479","article-title":"Preclinical characterization of AMPA receptor potentiator TAK-137 as a therapeutic drug for schizophrenia","volume":"7","author":"Tanaka","year":"2019","journal-title":"Pharmacol. Res. Perspect."},{"issue":"2\u20133","key":"10.1016\/j.jpsychires.2025.04.019_bib35","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0920-9964(03)00009-4","article-title":"Amphetamine-sensitized animals show a sensorimotor gating and neurochemical abnormality similar to that of schizophrenia","volume":"64","author":"Tenn","year":"2003","journal-title":"Schizophr. Res."},{"issue":"5663","key":"10.1016\/j.jpsychires.2025.04.019_bib36","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1126\/science.1090262","article-title":"Dynamic interaction of stargazin-like TARPs with cycling AMPA receptors at synapses","volume":"303","author":"Tomita","year":"2004","journal-title":"Science"},{"issue":"1\u20133","key":"10.1016\/j.jpsychires.2025.04.019_bib37","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.schres.2013.01.031","article-title":"Abnormal N-linked glycosylation of cortical AMPA receptor subunits in schizophrenia","volume":"146","author":"Tucholski","year":"2013","journal-title":"Schizophr. Res."},{"issue":"51","key":"10.1016\/j.jpsychires.2025.04.019_bib38","doi-asserted-by":"crossref","first-page":"22308","DOI":"10.1073\/pnas.1010025108","article-title":"Homeostatic regulation of glutamatergic transmission by dopamine D4 receptors","volume":"107","author":"Yuen","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"issue":"3","key":"10.1016\/j.jpsychires.2025.04.019_bib39","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.neuron.2019.08.001","article-title":"Phase separation-mediated TARP\/MAGUK complex condensation and AMPA receptor synaptic transmission","volume":"104","author":"Zeng","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.jpsychires.2025.04.019_bib40","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.schres.2020.03.037","article-title":"Functional impairment of cortical AMPA receptors in schizophrenia","volume":"249","author":"Zeppillo","year":"2022","journal-title":"Schizophr. Res."},{"issue":"2\u20133","key":"10.1016\/j.jpsychires.2025.04.019_bib41","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.schres.2014.07.054","article-title":"Glutamate receptor 1 phosphorylation at serine 845 contributes to the therapeutic effect of olanzapine on schizophrenia-like cognitive impairments","volume":"159","author":"Zhang","year":"2014","journal-title":"Schizophr. Res."}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395625002432?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395625002432?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:03:37Z","timestamp":1777694617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022395625002432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":41,"alternative-id":["S0022395625002432"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2025.04.019","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antipsychotic-like pharmacological profile of the low impact ampakine CX691 (farampator): Implications for the use of low impact ampakines in the treatment of schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2025.04.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}